LabCorp Downgraded by Canaccord Genuity

Oct 25, 2018

|

NEW YORK (360Dx) – Following Wednesday's release of Laboratory Corporation of America's third-quarter financial results, which missed the consensus Wall Street estimates on the top and bottom lines, Canaccord Genuity today downgraded the company's shares to a Hold rating from a previous Buy.

The investment bank also lowered its price target on LabCorp's shares to $162 from $195.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

LabCorp Downgraded by Canaccord Genuity

To read the full story....

Breaking News

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval

360Dx Index Declines 4 Percent in February, Ending Streak of Gains

Featured White Papers

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

What's Popular?

Labs, Vendors Anticipate COVID-19 Vaccines to Boost Serology Testing Demand

Reference Labs Take Diverse Approaches to Mitigating COVID-19 Sample Shipping Delays

Mistakes Were Made in Regulation of SARS-CoV-2 Serology Tests, FDA Officials Acknowledge

AMP Survey Finds Significant Decline in Molecular Cancer Testing Due to COVID-19 Pandemic

Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

Sponsorships